Clinical trials: End Stage Heart Failure
End Stage Renal Disease
Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A
The primary purpose of this study is to test the feasibility of trials which change the dialysate (dialysis bath prescription) of potassium and bicarbonate according to a standardized algorithm and according to the results of…
- Trial name
- RADAR-A (NCT03519347)
- Testing
- Potassium Removal Maximization, Potassium Gradient Minimization, Alkalosis Avoidance
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- NYU Langone Health
Diabetic Retinopathy, Macular Degeneration
Advancing Understanding of Transportation Options
This Stage II randomized, controlled, longitudinal trial seeks to assess the acceptability, feasibility, and effects of a driving decision aid use among geriatric patients and providers.
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa
- Trial name
- AUTO (NCT04141891)
- Testing
- Driving Decision Aid, Older Drivers Website
- Where
- 3 sites in United States
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
End Stage Renal Disease, Coronary Artery Disease
Coronary Artery Disease Screening in Kidney Transplant Candidates
Kidney transplant candidates are at very high risk for coronary artery disease (CAD). The optimal strategy to monitor and maintain the cardiac fitness of patients awaiting kidney transplantation is unknown.
- Trial name
- CADScreening (NCT02082483)
- Testing
- Selective Screening
- Where
- 6 sites in Canada
- Volunteers
- 144 people
- Sponsor
- University of British Columbia
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Family Palliative and End-of-Life Care for Advanced Heart Failure
Overall objective is to test whether the 5-weekly family home palliative and end-of-life care (FamPALcare) intervention educational and supportive sessions will improve rural home end-of-life and palliative care (EOLPC) for…
- Trial name
- NCT04153890
- Testing
- FamPALcare
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- West Virginia University
Dilated Cardiomyopathy
Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy
Several studies have documented that transplantation of bone marrow-derived cells (BMC) following acute myocardial infarction is associated with a reduction in infarct scar size and improvements in left ventricular function and…
- Trial name
- NCT00629018
- Testing
- CD34+ autologous stem cell transplantation, Bone Marrow Stimulation, SC therapy
- Where
- Slovenia
- Volunteers
- 110 people
- Sponsor
- University Medical Centre Ljubljana
Complication of Hemodialysis, Cardiovascular Diseases
Sodium Thiosulfate Treatment of Vascular Calcification in ESRD
Cardiovascular disease is the major cause of death in the hemodialysis population and calcification of the major arteries (coronary, aorta, and carotid) are a play a central role in this process.
- Trial name
- NCT00568399
- Testing
- sodium thiosulfate
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Atrial Fibrillation, End Stage Renal Disease
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .
- Trial name
- RENAL-AF (NCT02942407)
- Testing
- apixaban, warfarin
- Where
- 58 sites in United States
- Volunteers
- 154 people
- Sponsor
- Christopher Granger, MD
End Stage Renal Disease Requiring Hemodialysis
Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug
Patients whose kidneys are no longer able to work as they should and require treatment to filter wastes from the blood (hemodialysis) are at high risk for blood clots that form in blood vessels (thrombosis) blocking blood flow…
- Trial name
- RE-THINc ESRD (NCT04534114)
- Testing
- Fesomersen sodium (BAY2976217)
- Where
- 69 sites in United States, Belgium and 13 more
- Volunteers
- 307 people
- Sponsor
- Bayer
Malignant Neoplasm, Leukemia, Lymphocytic, Chronic, B-Cell
Project to Improve Communication About Serious Illness - Pilot Study
This two-year pilot study will test whether a one-page "Jumpstart Form" will affect goals-of-care discussions in the hospital. This form will be provided to clinicians and will include patient-specific information about…
- Conditions
- Malignant Neoplasm, Leukemia, Lymphocytic, Chronic, B-Cell, Lung Disease Chronic, Congestive Heart Failure
- Trial name
- PICSI-P (NCT03746392)
- Testing
- Jumpstart Intervention
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of Washington
Cancer, Congestive Heart Failure (CHF)
Outlook Quality of Life Intervention Study
The purpose of this study is to determine whether discussions of life story, forgiveness, and future goals improve quality of life for patients with serious illness.
- Conditions
- Cancer, Congestive Heart Failure (CHF), Chronic Obstructive Pulmonary Disease (COPD), End Stage Renal Disease (ESRD)
- Trial name
- NCT01044290
- Testing
- Life Completion, Attention Control
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- VA Office of Research and Development
Heart Failure, Ventricular Dysfunction, Left
Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
The purpose is to study if HF treatment guided by NTproBNP in addition to clinical symptoms and signs is more effective than treatment guided by clinical symptoms and signs alone in patients with HF and left ventricular systolic…
- Trial name
- NCT00391846
- Testing
- Captopril, Enalapril, Lisinopril
- Where
- 39 sites in Sweden
- Volunteers
- 252 people
- Sponsor
- AstraZeneca
Arrhythmias, Cardiac
Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients
Hemodialysis patients have a rate of fatal arrhythmias that is 40 times greater than the general population, but the causes and types of fatal arrhythmias they experience is unclear.
- Trial name
- CARE-ESRD (NCT00932659)
- Testing
- continuous cardiac monitoring device (REVEAL, Medtronic)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Duke University
End-Stage Heart Failure, Bridge-to-Transplant LVAD Placement (BTT)
Development & Testing of a Decision Aid for LVAD Placement
The goal of this project is to develop a patient-centered decision aid for decision-making about end-stage heart failure treatment.
- Conditions
- End-Stage Heart Failure, Bridge-to-Transplant LVAD Placement (BTT), Destination Therapy LVAD Placement (DT), Refusal of LVAD Placement (Decliners)
- Trial name
- VADDA (NCT02248974)
- Testing
- LVAD Decision Aid
- Where
- 7 sites in United States
- Volunteers
- 98 people
- Sponsor
- Baylor College of Medicine
End Stage Renal Disease
Monitoring in Dialysis -- a Prospective, Multi-center, Single-arm, Non-randomized, Observational Study in Patients Who Are Undergoing Hemodialysis.
The primary objective of this study is to estimate the proportion of hemodialysis patients experiencing clinically significant cardiac arrhythmias over a 6-month period using continuous cardiac monitoring with an implanted…
- Trial name
- MiD (NCT01779856)
- Testing
- REVEAL Insertable Cardiac Monitor (ICM)
- Where
- 10 sites in United States, India
- Volunteers
- 81 people
- Sponsor
- Medtronic Corporate Technologies and New Ventures
Heart Failure, Congestive
Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure
Heart failure is a condition in which the heart is unable to pump enough blood to the body's other organs. A heart transplant may be necessary for some individuals with end-stage heart failure.
- Trial name
- NCT00383630
- Testing
- Intramyocardial injection of bone marrow mononuclear cells, Intramyocardial injection of CD34+ selected bone marrow mononuclear cells, LVAD alone
- Where
- 7 sites in United States
- Volunteers
- 1 people
- Sponsor
- Columbia University
Heart Failure, Heart-assist Devices
PCORI-1310-06998 Trial of a Decision Support Intervention for Patients and Caregivers Offered Destination Therapy Heart Assist Device
The left ventricular assist device (LVAD) is growing rapidly among people dying from end-stage heart failure who are unable to get a heart transplant.
- Trial name
- DECIDE-LVAD (NCT02344576)
- Testing
- DT LVAD Decision Support Intervention
- Where
- 6 sites in United States
- Volunteers
- 445 people
- Sponsor
- University of Colorado, Denver
End-Stage Renal Disease
Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial
The SPin-D Trial is a phase II randomized, double-blind, placebo-controlled, multi-center study of spironolactone (SPL) for patients with hemodialysis-dependent end-stage renal disease.
- Trial name
- SPin-D (NCT02285920)
- Testing
- Spironolactone
- Where
- 4 sites in United States
- Volunteers
- 129 people
- Sponsor
- University of Pennsylvania
Drug Use, Alcohol Use
Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions
This study will assess Specialized Community Disease Management (SCDM), an intervention which employs various evidence-based strategies to engage substance using co-morbid patients while in the hospital and follow them into the…
- Conditions
- Drug Use, Alcohol Use, Congestive Heart Failure, Pneumonia
- Trial name
- NCT02059005
- Testing
- Specialized Community Disease Management, Treatment As Usual
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Treatment Research Institute
Pulmonary Arterial Hypertension
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
The purpose of this study is to find out if spironolactone added to ambrisentan for Pulmonary Arterial Hypertension (PAH) will increase exercise capacity.
- Trial name
- NCT02253394
- Testing
- Ambrisentan plus Spironolactone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Brigham and Women's Hospital
Cardiovascular Diseases, Cardiovascular Abnormalities
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
The primary objective is to assess the effect of 2 dose levels of SNF472 (300 mg and 600 mg) compared to placebo on the progression of coronary artery calcium volume score over a 12-month (52 weeks) period in ESRD patients on HD
- Conditions
- Cardiovascular Diseases, Cardiovascular Abnormalities, Calcifications, Vascular, Endstage Renal Disease
- Trial name
- NCT02966028
- Testing
- SNF472
- Where
- 75 sites in United States, Spain and 1 more
- Volunteers
- 274 people
- Sponsor
- Sanifit Therapeutics S. A.